Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mossuz, P
Right arrow Articles by Praloran, V
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mossuz, P
Right arrow Articles by Praloran, V
Haematologica, Vol 89, Issue 10, 1194-1198
Copyright © 2004 by Ferrata Storti Foundation

Clinical Trial

Diagnostic value of serum erythropoietin level in patients with absolute erythrocytosis

P Mossuz, F Girodon, M Donnard, V Latger-Cannard, I Dobo, N Boiret, JC Lecron, C Binquet, C Barro, S Hermouet, and V Praloran

Laboratories of Hematology of Centre Hospitalier Universitaire, Grenoble, France. pmossuz@chu-grenoble.fr

BACKGROUND AND OBJECTIVES: The diagnosis of polycythemia vera (PV) is based on clinical and biological criteria defined by either the Polycythemia Vera Study Group (PVSG) or the World Health Organization (WHO). Both the PVSG and WHO PV criteria have proved helpful and are extensively used, yet diagnostic strategies and scheduling of biological investigations vary. We assessed the value of measuring serum erythropoietin (Epo) as a first intention diagnostic test in patients with absolute erythrocytosis (AE). DESIGN AND METHODS: Serum and bone marrow (BM) samples of 241 patients with a suspicion of erythrocytosis were collected in 8 hospital centers. One hundred and ninety had an absolute erythrocytosis (116 had PV, 66 had secondary erythrocytosis and 4 had idiopathic erythrocytosis). Serum Epo was assayed (ELISA) in 186. Statistical analysis (ROC curves) was used to define serum Epo thresholds that were specific for PV and secondary erythrocytosis and to analyze the diagnostic value of a low or high serum Epo level. RESULTS: A large majority of PV patients (87% or 101/116) had a serum Epo level below the normal range in healthy patients (3.3 IU/L), giving this value a specificity of 97% with a 97.8% positive predictive value for the diagnosis of PV. Statistical analysis (ROC curves) defined two thresholds allowing a specific and direct diagnosis of 65.6% (65/99) of untreated PV (Epo < 1.4 IU/L) and 19.7% (13/66) of those with secondary erythrocytosis (Epo > 13.7 IU/L). INTERPRETATION AND CONCLUSIONS: Based on these data, we propose that measurement of serum Epo level, a simple, reliable and inexpensive test, should be considered as a first intention diagnostic test for patients with absolute erythrocytosis.


This article has been cited by other articles:


Home page
 BloodHome page
J. L. Spivak and R. T. Silver
The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal
Blood, July 15, 2008; 112(2): 231 - 239.
[Full Text] [PDF]

Home page
 BloodHome page
R. Tiedt, H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, and R. C. Skoda
Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice
Blood, April 15, 2008; 111(8): 3931 - 3940.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
F. Girodon, E. Lippert, P. Mossuz, I. Dobo, N. Boiret-Dupre, J.-F. Lesesve, S. Hermouet, and V. Praloran
JAK2V617F detection and dosage of serum erythropoietin: first steps of the diagnostic work-up for patients consulting for elevated hematocrit
Haematologica, March 1, 2007; 92(3): 431 - 432.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. Boissinot, E. Lippert, F. Girodon, I. Dobo, M. Fouassier, C. Masliah, V. Praloran, and S. Hermouet
Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis.
Blood, November 1, 2006; 108(9): 3223 - 3224.
[Full Text] [PDF]

Home page
 BloodHome page
E. Lippert, M. Boissinot, R. Kralovics, F. Girodon, I. Dobo, V. Praloran, N. Boiret-Dupre, R. C. Skoda, and S. Hermouet
The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera
Blood, September 15, 2006; 108(6): 1865 - 1867.
[Abstract] [Full Text] [PDF]

Home page
 J. Mol. Diagn.Home page
D. P. Steensma
JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology
J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
G. Wernig, T. Mercher, R. Okabe, R. L. Levine, B. H. Lee, and D. G. Gilliland
Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Blood, June 1, 2006; 107(11): 4274 - 4281.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
A. I. Schafer
Molecular basis of the diagnosis and treatment of polycythemia vera and essential thrombocythemia
Blood, June 1, 2006; 107(11): 4214 - 4222.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
P. Mossuz, F. Girodon, S. Hermouet, I. Dobo, E. Lippert, M. Donnard, V. Latger-Cannard, N. Boiret, V. Praloran, and J. C. Lecron
Serum Erythropoietin Measured by Chemiluminescent Immunometric Assay: An Accurate Diagnostic Test for Absolute Erythrocytosis
Clin. Chem., June 1, 2005; 51(6): 1018 - 1021.
[Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2004 by the Ferrata Storti Foundation.